BMC Endocrine Disorders (Sep 2021)

A novel heterozygous mutation of CHD7 gene in a Chinese patient with Kallmann syndrome: a case report

  • Weiwei Xu,
  • Weibin Zhou,
  • Haiyang Lin,
  • Dan Ye,
  • Guoping Chen,
  • Fengqin Dong,
  • Jianguo Shen

DOI
https://doi.org/10.1186/s12902-021-00836-0
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Background Variants of chromodomain helicase DNA binding protein 7 (CHD7) gene are commonly associated with Kallmann syndrome (KS) and account for 5–6% of idiopathic hypogonadotropic hypogonadism (IHH) cases. Here we report a novel mutation of CHD7 gene in a patient with KS, which may contribute to the better understanding of KS. Case presentation A 29-year-old male patient with KS and a chief complaint of delayed puberty for 13 years (Tanner B Stage T mutation of TCD7 gene (p.G4856V) was detected, whereas none of his family members had this mutation. Human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) were injected for three times/week to treat idiopathic hypogonadotropic hypogonadism (IHH). After several months of therapy, the patient’s health condition improved. His testicles became larger, and his secondary sexual characteristics improved after treatment. Conclusion Exploration of the novel splice-site mutation of CHD7 may further our current understanding of KS.

Keywords